Logo

Neurocrine Signs a License Agreement with Sosei Heptares to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

Share this

Neurocrine Signs a License Agreement with Sosei Heptares to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

Shots:

  • Sosei Heptares to receive $100M up front & R&D fundings, ~$1.5B upon achievement of development & regulatory milestones of licensed product, $1.1B in commercial milestone along with royalties on net sales of products. Neurocrine will lead development costs related to programs globally except M1 agonists
  • Sosei Heptares retains rights to develop M1 agonists in Japan for any indication while Neurocrine gets co-development & profit share options along with development & commercialization rights of M4, M1 & dual M1/M4 receptor agonists for a neurological disorder
  • The P-II study of HTL-0016878 in schizophrenia is expected to initiate in 2022 & P-I studies for dual M1/M4 & M1 agonists in 2023

Ref: Neurocrine | Image: Neurocrine


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions